ClinicalTrials.gg

TargetBeta

CD40LG

CD40 ligand · also CD40L, TRAP, gp39, hCD40L · CD molecules

7 programs in company-led studies act on CD40LG, from 7 companies: 4 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
frexalimabSanofiphase 3119 running–the company's pipeline
dapirolizumab pegolruleUCBphase 383 running–ChEMBL
tegoprubartruleEledon Pharmaceuticalsphase 383 running–ChEMBL
dazodalibepruleAmgenphase 392 running–ChEMBL
OPT101ruleOp-Tphase 242 running–the studies' text
ravagalimabruleAbbViephase 241 running–ChEMBL
TNX-1500ruleTonix Pharmaceuticalsphase 110 running–the studies' text

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.